Stock Events

Stock Events

NuCana 

0
0
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-34.22MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow N04A.STU. It's not an investment recommendation.
NVIDIA
18
NVDA
Schwab US Dividend Equity
11
SCHD
YieldMax MSTR Option Income Strategy
11
MSTY
Tesla
10
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Merck
MRK
Mkt Cap367.07B
Merck & Co., Inc. is a global healthcare company that develops medications in oncology, making it a direct competitor to NuCana's cancer-focused therapies.
Bristol-Myers Squibb
BMY
Mkt Cap128.41B
Bristol-Myers Squibb operates in the same oncology and hematology space, competing with NuCana in the development of cancer treatments.
Astrazeneca
AZN
Mkt Cap258.35B
AstraZeneca PLC focuses on the discovery and development of products in oncology, competing with NuCana in cancer drug development.
Pfizer
PFE
Mkt Cap163.41B
Pfizer Inc. has a broad portfolio that includes oncology, directly competing with NuCana's cancer treatment research and development.
Gilead Sciences
GILD
Mkt Cap187.15B
Gilead Sciences, Inc. is involved in the research and development of oncology drugs, making it a competitor in the cancer treatment market.
AMGEN
AMGN
Mkt Cap224.15B
Amgen Inc. focuses on human therapeutics, including oncology, which puts it in competition with NuCana in the cancer treatment sector.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG engages in the pharmaceuticals and diagnostics business in oncology, directly competing with NuCana's cancer therapies.
Novartis
NVS
Mkt Cap276.48B
Novartis AG operates in the development and marketing of healthcare products, including oncology, competing with NuCana in cancer treatment innovations.
Abbvie
ABBV
Mkt Cap467.12B
AbbVie Inc. has a strong focus on oncology, making it a competitor in the development of cancer treatments similar to NuCana's focus.
Lilly(Eli) &
LLY
Mkt Cap1.05T
Eli Lilly and Company is engaged in the discovery, development, and marketing of pharmaceutical products, including for cancer, competing with NuCana in the oncology space.

About

NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States and the United Kingdom.
Show More
CEO
Hugh Stephen Griffith
Employees
12
Country
United Kingdom
ISIN
US67022C1062
WKN
000A41DTP

Listings

MU
DE
N04A.MU
STU
DE
N040.STU
MU
DE
N040.MU
STU
DE
N04A.STU

0 Comments

Share your thoughts

FAQs

What is NuCana stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange NuCana stocks are traded under the ticker N04A.STU.
What is NuCana revenue for the last year?▼
NuCana revenue for the last year amounts to 0 EUR.
What is NuCana net income for the last year?▼
N04A.STU net income for the last year is -34.22M EUR.
How many employees does NuCana have?▼
As of October 5, 2026, the company has 12 employees.
In which sector is NuCana located?▼
NuCana operates in the Health & Wellness sector.
When did NuCana complete a stock split?▼
The last stock split for NuCana was on April 16, 2024 with a ratio of 1:25.
Where is NuCana headquartered?▼
NuCana is headquartered in Edinburgh, United Kingdom.